The 2 Likely Reasons Novavax Rocketed Higher by 25% in November
Shares of Novavax surged by 25% during the month of November, according to data from S&P Global Market Intelligence. The reasoning for the move appears to be traceable to two catalysts: encouraging third-quarter results and also the expectation of a topline readout in its phase 1/2 clinical trial involving NanoFlu before the end of the year
View the full story here: http://www.fool.com/investing/2017/12/06/the-2-likely-reasons-novavax-inc-rocketed-higher-b.aspx